Anixa Biosciences Income Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Revenue	-	-	0.21	-	0.51
Cost of Revenue	-	-	0.16	-	0.39
Gross Profit	-	-	0.05	-	0.13
Selling, General & Admin	6.63	7.44	6.29	7.17	7.07
Research & Development	5.07	6.4	4.77	6.7	6.19
Operating Expenses	11.7	13.83	11.06	13.88	13.26
Operating Income	-11.7	-13.83	-11.01	-13.88	-13.14
Interest & Investment Income	0.67	1.13	1.08	0.1	0
EBT Excluding Unusual Items	-11.03	-12.7	-9.93	-13.77	-13.13
Gain (Loss) on Sale of Assets	-	-	-	-	0.01
Pretax Income	-11.03	-12.7	-9.93	-13.77	-13.13
Earnings From Continuing Operations	-11.03	-12.7	-9.93	-13.77	-13.13
Minority Interest in Earnings	0.1	0.14	0.12	0.18	0.17
Net Income	-10.93	-12.55	-9.81	-13.6	-12.95
Net Income to Common	-10.93	-12.55	-9.81	-13.6	-12.95
Shares Outstanding (Basic)	32	32	31	30	29
Shares Outstanding (Diluted)	32	32	31	30	29
Shares Change (YoY)	1.74%	2.96%	1.99%	6.28%	28.57%
EPS (Basic)	-0.34	-0.39	-0.32	-0.45	-0.45
EPS (Diluted)	-0.34	-0.39	-0.32	-0.45	-0.45
Free Cash Flow	-7.17	-7.34	-6.21	-6.49	-4.94
Free Cash Flow Per Share	-0.22	-0.23	-0.20	-0.21	-0.17
Gross Margin	-	-	23.33%	-	24.80%
Operating Margin	-	-	-5243.33%	-	-2565.63%
Profit Margin	-	-	-4671.91%	-	-2530.08%
Free Cash Flow Margin	-	-	-2956.67%	-	-964.45%
EBITDA	-	-	-	-	-13.1
D&A For EBITDA	-	-	-	-	0.04
EBIT	-11.7	-13.83	-11.01	-13.88	-13.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.